Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of QLS1410 in primary aldosteronism
CTR20261507Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLS1410 in primary aldosteronism (PA), sponsored by Qilu Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
QLS1410
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on CTR20261507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261507.